One Heart Hall Chairman Yu Hongxuan: selection of excellence is the pharmacy's way of lasting survival.

From January to June 2020, sales revenue growth in regional stores outside Yunnan Province reached 25.31% YoY, higher than the revenue growth rate of the company's consolidated statement calibre.
as of June 30, 2020, the company had 6,683 direct chain stores, 5,727 stores with health insurance credit card qualification, and 39.20% of regional stores outside Yunnan Province.
the long-lasting survival of the pharmacy comes from the strict control of the selection, the introduction of varieties of excellence.
recently in an interview with Sina Pharmaceuticals, One Heart Hall Chairman Yu Hongxuan revealed the selection criteria of One Heart Hall chain pharmacy: mainly consider the therapeutic effect of the product, as well as the product in the market consumer recognition of it.
the introduction of new varieties, we will first let suppliers or pharmaceutical companies provide some samples to try.
, we will also go to the enterprise to conduct research to see if the size of the enterprise, product quality and other aspects are trustworthy, will consider whether to choose to purchase the varieties it produces.
", said Mr. Yu.
the quality of drugs directly related to the treatment effect of patients, in the quality control of drugs, in strict accordance with the "Drug Management Quality Management Code" (GSP) to implement, under the management of GSP drugs can be clearly traced, from production enterprises to sales enterprises, as well as to the hands of consumers can be traced.
now online and offline are competing for passenger traffic, it is understood that when attracting passenger flow, will first consider different patients, consumers personalized needs.
followed by service upgrades to provide customers with more choices and gain more trust.
again, we pay great attention to the creation and training of practicing pharmacists, the use of professional service skills, to guide customers to buy the right drugs, the continuous pursuit of providing consumers with professional, intimate services.
Overall, no matter how the pharmaceutical industry environment changes, one heart will uphold its service purposes, "one heart for the people, all-hearted service", to serve every patient and consumer, and constantly meet customer needs, to provide customers with health protection.
this year, the slow-motion business has grown better.
is also worth noting that in order to further enhance the stickiness of old customers and attract more new customers to new traffic, One Heart Hall this year began to build health care stations in all regional stores, the first half of the construction of 344.
"how to let consumers trust your brand, trust your service, to trust your service connotation of drug quality, efficacy? I think brands can supply the drugs that consumers want to buy, and brands can improve their services to help consumers buy the drugs they need, so brands resonate with consumers.
": "I don't know."
in the cooperation with brand enterprises, Mr. Yu mentioned the case of cooperation between Yipson and Ipsum China.
1975, Smida ® was launched in France, mainly for the treatment of diarrhoea, and is a star product of Ipsos.
1992, the product entered the Chinese market, has become a mature, high-profile star products.
more than 2000 years, Smida and One Heart close cooperation, Smida sales have exceeded 10 million yuan, and has been in a growing trend.
With the deepening of cooperation between pharmacies and pharmaceutical brands, on the one hand, through promotional activities to really give benefits to consumers, through community events, online live broadcasts and other ways to help consumers raise health awareness, to provide consumers with diversified services.
, on the other hand, consumer trust in pharmacies stems from the pharmacy's hard work, from a long-standing relentless pursuit and persistence, and from providing consumers with comprehensive health solutions.
2018, the country launched the "4 plus 7" band procurement, and then spread to the whole country and continue to expand.
in the context of mining, China's pharmaceutical industry has undergone great changes, in the future, the collection of unseeded brand drug brand value will still be greatly released at the retail end.
chen Jialin, general manager of Yipson, revealed that most of the mature products of multinational pharmaceutical companies, and innovative drug layout in the future will focus on retail pharmacies, grass-roots markets and other markets, including Ipsante, some enterprises are currently taking such a path.
Hongxuan revealed that in the face of the deepening of medical reform, the adjustment of medical policy, the whole mind has been fully prepared to adapt to national policies, adapt to the needs of the market, society, consumers, at the same time, combined with the development of enterprises themselves, positioning a good direction, development goals, do not forget the first heart, all the way forward.
This year marks the 45th anniversary of Smida's global listing, and he said he looks forward to providing better help and efficacy to more patients in the market in the future, wishing Ipsum China and One Heart a step forward in their cooperation to achieve co-creation and win-win results.
.